Ulf Sengutta’s Post

CelluSPOT Synthese im Peptidsynthesizer MultiPep 2 Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers https://lnkd.in/eGFnuFwJ #Peptode #peptide #peptidsynthesizer #peptidesynthesis #CelluSPOT #Multipep #CEM #Intavis #medikamente

CelluSPOT Synthese im Peptidsynthesizer MultiPep 2 Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers https://lnkd.in/euSWUk8p #Peptode #peptide #peptidsynthesizer #peptidesynthesis #CelluSPOT #Multipep #CEM #Intavis  

New RAS dialogue! Understanding and overcoming resistance to KRAS G12C inhibitors remains a key focus in the fight against RAS-driven cancers. In a new blog post, Drs. Mira and Nokin describe non-genetic methods of resistance to G12C inhibitors that bind to the inactive, GDP-bound form of the protein. They observed an increase in active GTP-loaded KRAS in patient samples, and argue for the dual inhibition of both active and inactive KRAS as a more effective therapeutic strategy.

⏰ Time’s running out! SECURE YOUR SPOT & discover the pivotal role of functional #cellbasedassays for characterizing novel #therapeutics & biosimilars targeting #cytokines in inflammation & oncology. Hear about case studies employing Eurofins DiscoverX®’s assays for monitoring receptor dimerization & pathway activation targeting cytokines including IL-23, IL-12, IL-17, & IL-4/IL-13.  And many more learning outcomes…https://lnkd.in/g-G4exDR

Foundation Medicine and Syndax Pharmaceuticals join forces to develop a tool targeting acute myeloid leukemia (AML) patients with NPM1 mutations. NPM1 mutations are prevalent in AML, affecting about 30% of newly diagnosed patients. Currently, there are no approved targeted treatments for these patients, with a 50% overall survival rate after five years. Syndax's revumenib presents promising new treatment avenues for NPM1-mutated AML. Foundation Medicine plans to create a next-gen sequencing diagnostic on its FoundationOne® Heme platform to better identify suitable patients. If approved, this assay could revolutionize personalized AML treatment, marking Foundation Medicine's debut as a companion diagnostic provider and cementing its leadership in the field. This collaboration underscores the significance of genomic profiling and therapeutic target development in combatting blood cancers, aiming to enhance patient outcomes and treatment decisions. Learn more: https://lnkd.in/dHJNWsc8 Neil Gallagher MD PhD Norman Nagl Shaliny Kushwaha #FoundationMedicine #SyndaxPharmaceuticals #AML #CompanionDiagnostic #GenomicProfiling #BloodCancers #PrecisionMedicine

Clinical Trials Updates: Takeda's Iclusig (ponatinib) has received accelerated approval from the FDA for treating newly diagnosed adults with a rare type of leukaemia. This approval marks the first time a targeted therapy has been approved in the US as the initial treatment for Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph-positive ALL). This typeof leukaemiaa affects around 25% of adults with ALL and is identified by the presence of an abnormal gene called the Philadelphia chromosome. Iclusig, a kinase inhibitor, was previously approved in the US for various leukemia patients. This additional approval was supported by positive results from the PhALLCON study, showing Iclusig-treated patients achieved over two-fold improvement in minimal residual disease-negative complete remission. Congrats to Takeda once again for the successful approval! #medicalaffairs #clinicaldevelopment #clinicalcareers #FDAapproval #medicalcareers https://lnkd.in/efmHKAXQ

For anticancer drugs with a narrow therapeutic window, there is a delicate balance between efficacy and toxicity, thus it is pivotal to administer the right dose from the first administration onwards. Exposure of pemetrexed, a cytotoxic drug used in lung cancer treatment, is dictated by kidney function. To facilitate optimized dosing of pemetrexed, accurate prediction of drug clearance is pivotal. In the journal of anticancer chemotherapy and pharmacology Nikki Bleijs - de Rouw published her findings on endogenous biomarkers to predict pemetrexed pharmacokinetics. Nikki Bleijs - de Rouw showed that the combined CKD-EPI equation using both cystatin C and serum creatinine performed best in terms predicting pharmacokinetics of pemetrexed. This may facilitate dose individualization of pemetrexed. Read all about it here: https://lnkd.in/ehD98MUp Radboud Applied Pharmacometrics Radboudumc Radboudumc wetenschap

An application of pharmacometrics to individualize dosing of pemetrexed.

This paper suggests that a novel CEACAM6-targeted antibody–drug conjugate (ADC) named EBET for PDAC therapy. CEACAM6-EBET ADC delivers BET protein degrader via CEACAM6 antibody, Modulation of PDAC Stromal : Bystander efficacy on CEACAM6-negative Cancer-Associated Fibroblasts (CAFs) inhibits STAT3 signaling, contributing to break down of the PDAC stromal. Authors say that this dual impact on PDAC cells and stroma is a key feature. https://lnkd.in/g43BaqPm

We know that solid tumors are particularly challenging to treat due to several factors, including their complex microenvironment and their ability to resist penetration by therapeutic agents. Here are some factors we could likewise note about the impenetrable nature of solid tumors: -Complex microenvironment -Hypoxia -Poor drug penetration -Heterogeneity -Last but not least, Drug resistance Therefore, I would argue that any development toward such a life-threatening disease represents a significant advancement against cancer - and survival rate improvements.